论文部分内容阅读
目的观察紫杉醇联合顺铂治疗中晚期食管癌的疗效及安全性。方法52例中晚期食管癌患者随机分为两组。治疗组(PTX+DDP):PTX:175mg/m2,静滴3h第一天;DDP75mg/m2,静滴第1天。21天为1周期。对照组(5-Fu+DDP):5-Fu750mg/m2/d,静滴第1～5天;DDP75mg/m2,静滴第1天,21d为1周期。结果治疗组25例食管癌患者的有效率为76%;对照组27例的有效率为48.15%;两组比较有显著性差异(P<0.05)。治疗组白细胞减少发生率高于对照组,但差异无统计学意义,脱发、肌肉关节痛发生率明显高于对照组(P<0.05)。结论紫杉醇联合顺铂治疗中晚期食管癌疗效优于5-Fu+DDP,疗效肯定。不良反应有所增加,但可耐受。
Objective To observe the efficacy and safety of paclitaxel combined with cisplatin in the treatment of advanced esophageal cancer. Methods 52 patients with advanced esophageal cancer were randomly divided into two groups. Treatment group (PTX + DDP): PTX: 175mg / m2, intravenous infusion 3h on the first day; DDP75mg / m2, intravenous infusion on the first day. 21 days for 1 cycle. The control group (5-Fu + DDP): 5-Fu750mg / m2 / d, intravenous drip 1 ~ 5 days; DDP75mg / m2, intravenous drip 1 day, 21d for 1 cycle. Results In the treatment group, the effective rate of 25 cases of esophageal cancer was 76%. The effective rate of the control group was 48.15%. There was significant difference between the two groups (P <0.05). The incidence of leukopenia in the treatment group was higher than that in the control group, but the difference was not statistically significant. The incidence of hair loss and muscle joint pain was significantly higher than that of the control group (P <0.05). Conclusion Paclitaxel combined with cisplatin in the treatment of advanced esophageal cancer curative effect is better than 5-Fu + DDP, curative effect is definite. Adverse reactions have increased, but can be tolerated.